The Center for Biosimilars® recaps the top 5 articles for the week of May 7, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 7.
Number 5: A bibliometric analysis demonstrates that the quality and quantity of research on biosimilars is on the rise.
Number 4: Biosimilar developer Coherus announced that it has resubmitted a Biologics License Application for its pegfilgrastim biosimilar after receiving a Complete Response Letter for the drug in 2017.
Number 3: The European Medicines Agency’s 2017 report says that last year saw the agency’s highest-ever number of biosimilar applications.
Number 2: Research presented at the British Society for Rheumatology’s Annual Conference, held this month in Liverpool, United Kingdom, demonstrates that biosimilars are increasingly used as first-line treatment for juvenile idiopathic arthritis.
Number 1: Avalere has issued a new report that finds that utilization management strategies, including preferential formulary design and step therapy, are impacting the uptake of biosimilars in the United States.
Finally, last week, our e-newsletter asked for your thoughts on where the treatment of psoriasis is headed.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.